Home Cart Sign in  
Chemical Structure| 78755-81-4 Chemical Structure| 78755-81-4

Structure of Flumazenil
CAS No.: 78755-81-4

Chemical Structure| 78755-81-4

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Flumazenil is a non-selective antagonist of benzodiazepine towards α1, α2, α3 or α5-containing GABAA receptors.

Synonyms: Ro 15-1788; Ro 1722; Flumazenil, Flumazepil, Anexate, Romazicon, Lanexat, Ro 15-1788, Ro 15 1788, Ro 151788

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Flumazenil

CAS No. :78755-81-4
Formula : C15H14FN3O3
M.W : 303.29
SMILES Code : O=C(C1=C2CN(C(C3=CC(F)=CC=C3N2C=N1)=O)C)OCC
Synonyms :
Ro 15-1788; Ro 1722; Flumazenil, Flumazepil, Anexate, Romazicon, Lanexat, Ro 15-1788, Ro 15 1788, Ro 151788
MDL No. :MFCD00242764
InChI Key :OFBIFZUFASYYRE-UHFFFAOYSA-N
Pubchem ID :3373

Safety of Flumazenil

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H315-H319-H335
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

Target
  • GABAA receptor

In Vitro:

Cell Line
Concentration Treated Time Description References
Human colonic organoids 1 μM 1-hour pretreatment Flumazenil increased the number and size of human organoids post 5-FU/irradiation treatment. PMC9499828
Human colonic organoids 1 μM 48 hours Flumazenil alleviated 5-FU or irradiation-induced toxicity in human colonic organoids, increasing the number and size of organoids. PMC9499828
HEK293T cells 3 µM Flumazenil inhibited isoflurane-mediated GABA current enhancement and exhibited weak agonist activity at 1 μM PMC5326685

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice 5-FU or irradiation-induced intestinal injury model Intraperitoneal injection 1 mg/kg 6 days (5-FU) or single dose (irradiation) Flumazenil significantly alleviated 5-FU or irradiation-induced intestinal injury in mice, increasing the number of TACs, proliferative capacity, and OLFM4+ ISCs, and reducing DNA double-strand breaks. PMC9499828
Sprague-Dawley rats Isoflurane anesthesia model Intravenous injection 0.4 mg/kg Single administration Flumazenil hastened behavioral and neurophysiological markers of emergence from isoflurane anesthesia and mitigated the increase in post-anesthesia sleep time PMC5326685
Rhesus monkey Rhesus monkey model Intravenous injection 1 mg/kg Single dose, duration 90 minutes To evaluate the in vivo pharmacokinetics of [18F]AH114726 and [18F]GEH120348 in non-human primates and directly compare them with [11C]FMZ. Results showed that [18F]AH114726 had pharmacokinetics most similar to [11C]FMZ, while [18F]GEH120348 showed higher initial brain uptake but slower clearance. PMC7730330
Planarians (Dugesia dorotocephala) Drug withdrawal model Immersion 10 µM 1-hour exposure, 5-minute test Flumazenil significantly antagonized the withdrawal effects induced by three benzodiazepine receptor agonists (midazolam, clorazepate, and zolpidem), as evidenced by a significant prevention of the reduction in pLMV. PMC2697456
Mice Anxiety and anticonvulsant models Intraperitoneal injection 2 mg/kg Single dose, administered 15 minutes before NPT To evaluate the antagonistic effect of Flumazenil on the anxiolytic-like and anticonvulsant effects of NPT. Results showed that Flumazenil significantly reversed the anxiolytic-like and anticonvulsant effects of NPT. PMC10142729
Rhesus monkey Rhesus monkey model Intravenous injection 1 mg/kg Single dose, duration 90 minutes To evaluate the in vivo pharmacokinetics of [18F]AH114726 and [18F]GEH120348 in non-human primates and directly compare them with [11C]FMZ. Results showed that [18F]AH114726 had pharmacokinetics most similar to [11C]FMZ, while [18F]GEH120348 showed higher initial brain uptake but slower clearance. PMC3769461

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00000246 Substance-Related Disorders PHASE2 COMPLETED 1994-12-01 Yale University, Psychiatry, N... More >>ew Haven, Connecticut, 06519, United States Less <<
NCT01183312 Hypersomnia|Primary Hypersomni... More >>a|Idiopathic Hypersomnia|Narcolepsy Without Cataplexy Less << PHASE1|PHASE2 COMPLETED 2025-01-12 Emory Sleep Center, Atlanta, G... More >>eorgia, 30329, United States Less <<
NCT06563063 Stomach Neoplasm COMPLETED 2023-12-01 Severance hospital, Seoul, Kor... More >>ea, Republic of Less <<
NCT01655914 Insomnia PHASE1 COMPLETED 2025-08-12 Rambam Health Care Campus, Hai... More >>fa, 31096, Israel Less <<
NCT00997087 Obsessive Compulsive Disorder PHASE2 TERMINATED 2025-12-12 James G. Sullivan, MD, Birming... More >>ham, Alabama, 35215, United States Less <<
NCT05382806 Flumazenil Adverse Reaction|Am... More >>bulatory Surgery|Postoperative Nausea|Remimazolam Less << COMPLETED 2023-05-13 Konkuk University Medical Cent... More >>er, Seoul, Seoul-T'ǔkpyǒlshi, 05030, Korea, Republic of Less <<
NCT05681377 Anesthesia, General PHASE4 COMPLETED 2023-08-11 Korea University Guro Hospital... More >>, Seoul, 08308, Korea, Republic of Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

3.30mL

0.66mL

0.33mL

16.49mL

3.30mL

1.65mL

32.97mL

6.59mL

3.30mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories